Integra Lifesciences (NASDAQ:IART) had its target price hoisted by JMP Securities from $57.00 to $60.00 in a research report released on Wednesday morning. They currently have a market outperform rating on the life sciences company’s stock.
Other research analysts also recently issued research reports about the company. TheStreet upgraded Integra Lifesciences from a c+ rating to a b- rating in a report on Wednesday, February 7th. Oppenheimer set a $58.00 price objective on Integra Lifesciences and gave the stock a buy rating in a report on Tuesday, December 12th. UBS Group restated a buy rating and set a $57.00 price target on shares of Integra Lifesciences in a report on Tuesday, October 31st. Barclays restated a hold rating and set a $53.00 price target on shares of Integra Lifesciences in a report on Tuesday, January 9th. Finally, Zacks Investment Research upgraded Integra Lifesciences from a sell rating to a hold rating in a report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $53.55.
Integra Lifesciences (NASDAQ:IART) traded down $0.95 on Wednesday, hitting $52.73. The stock had a trading volume of 748,800 shares, compared to its average volume of 511,504. The stock has a market capitalization of $4,212.67, a P/E ratio of 63.56, a P/E/G ratio of 1.71 and a beta of 0.67. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49. Integra Lifesciences has a 1 year low of $40.51 and a 1 year high of $56.42.
In related news, Director Keith Bradley sold 15,658 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $55.00, for a total transaction of $861,190.00. Following the transaction, the director now owns 37,074 shares in the company, valued at approximately $2,039,070. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 21.50% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Integra Lifesciences by 3.4% during the 4th quarter. BlackRock Inc. now owns 8,135,552 shares of the life sciences company’s stock worth $389,367,000 after acquiring an additional 269,484 shares during the period. Champlain Investment Partners LLC grew its holdings in shares of Integra Lifesciences by 2.4% during the 4th quarter. Champlain Investment Partners LLC now owns 4,646,075 shares of the life sciences company’s stock worth $222,361,000 after acquiring an additional 110,355 shares during the period. Clearbridge Investments LLC grew its holdings in shares of Integra Lifesciences by 0.3% during the 4th quarter. Clearbridge Investments LLC now owns 1,294,287 shares of the life sciences company’s stock worth $61,945,000 after acquiring an additional 3,561 shares during the period. Orbimed Advisors LLC grew its holdings in shares of Integra Lifesciences by 155.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock worth $55,069,000 after acquiring an additional 664,000 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Integra Lifesciences by 48.3% during the 3rd quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock worth $52,232,000 after acquiring an additional 336,930 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3231058/integra-lifesciences-iart-price-target-raised-to-60-00-at-jmp-securities.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.